

MD Anderson Cancer Center Clinical Trials at the Regional Care Centers

To refer online: <https://my.mdanderson.org>

To refer a patient, call the Regional Care Center main line (Bay Area, Katy, The Woodlands, Sugar Land): 713-745-9940

To discuss Regional Care Center clinical trials, call Joan Blais, R.N. (713-792-5625) or Marie Aaron, R.N. (713-792-6515)

10/2014

Breast Cancer

SWOG S1207 (P.I. Mariana Chavez Mac Gregor, M.D.):

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

CALGB 40903 (P.I. Isabella Bedrosian, M.D.): Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women Estrogen Receptor Positive Ductal Carcinoma In Situ (DCIS)

SWOG S1007 (P.I. Gabriel N. Hortobagyi, M.D.): Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less

2012-0167 (P.I. Ricardo Alvarez, M.D.): Phase II Randomized Neoadjuvant Study of Sequential Eribulin Followed by FAC/FEC-Regimen Compared to Sequential Paclitaxel Followed by FAC/FEC-Regimen in Patients with Early-Stage Breast Cancer Not Overexpressing HER2

NSABPB43 (P.I. Henry Kuerer, M.D.): Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Gynecological Cancers

2012-0759 (P.I. Jubilee Brown, M.D.): Randomized Open-Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients with Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

2008-0118 (P.I. Kathleen Schmeler, M.D.): Conservative Surgery for Women with Low-Risk, Early Stage Cervical Cancer

RTOG 1203 (P.I. Ann H. Klopp, M.D.): A Randomized Phase III Study of Standard Versus IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer

2011-0800 (P.I. Lois M. Ramondetta, M.D.): Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients

2012-0543 (P.I. Pamela Soliman, M.D.): Phase II, Single Arm Study of RAD001, Letrozole and Metformin in Patients with Advanced or Recurrent Endometrial Carcinoma

2008-0094 (P.I. Shannon Westin, M.D.): Phase II Study of the Levonorgestrel Intrauterine Device (Mirena) to Treat Complex Atypical Hyperplasia and Grade 1 Endometrioid Endometrial Carcinoma

GOG 0225 (P.I. Diane C. Bodurka, M.D.): Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

Head and Neck Cancers

2009-0395 (P.I. William N. William Jr., M.D.): Phase II

Randomized, Placebo-Controlled Study of Docetaxel and Cisplatin/Carboplatin with or without Erlotinib in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.

2009-0847 (P.I. James Welsh, M.D.): Phase I/II Study of

Evaluating the Safety and Efficacy of Using a Simultaneous Integrated Boost for Dose Escalation in Patients with Esophageal Cancer.

RTOG1216 (P.I. Michael E. Kupferman, M.D.) Randomized

Phase II/III Trial of Surgery And Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel And Cetuximab For High-Risk Squamous Cell Cancer of the Head and Neck

Colon Cancer

CALGBSWOG C80702 (P.I. Cathy Eng, M.D.): Phase III

Trial of Six Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage 3 Colon Cancer.

Lung Cancer

RTOG 1306 (P.I. Anne S. Tsao, M.D.): A Randomized

Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)